{"entity":{"id":"nct03606967","kind":"trial","name":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of carboplatin, durvalumab, gemcitabine, nab-paclitaxel and other drugs in triple-negative breast cancer, run by National Cancer Institute (NCI), now recruiting.","summary":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer is a phase 2, randomised interventional study registered as NCT03606967 by National Cancer Institute (NCI), with a registry enrolment figure of 86 participants, started 2021-04-13 and due to reach its primary completion in 2026-12-30. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Carboplatin; Computed Tomography; Durvalumab; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Nab-paclitaxel; Personalized Synthetic Long Peptide Vaccine; Poly ICLC; Sacituzumab Govitecan; Tremelimumab. Conditions listed: Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma. Triple-negative eligibility wording from the registry: \"* Patients must have a histologically confirmed diagnosis of metastatic invasive triple negative breast cancer\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03606967","url":"https://clinicaltrials.gov/study/NCT03606967"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc","checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","durvalumab","gemcitabine","nab-paclitaxel","sacituzumab-govitecan","tremelimumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03606967","phase":"2","setting":"Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer","sponsor":"National Cancer Institute (NCI)","enrolled":86,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03606967/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}